FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

CGMP Violations at Guangzhou Baiyunshan

FDA warns Chinas Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd. about CGMP violations in its production of finished drugs.

latest-news-card-1
Federal Register

Enhancing Diversity in Pediatric Drug Development Workshop

Federal Register notice: FDA announces a 9/6 public workshop entitled Enhancing Diversity in Therapeutics Development for Pediatric Patients to discus...

latest-news-card-1
Human Drugs

Man Sentenced for Misbranded Drugs

The Justice Department says a Virginia man who pleaded guilty to distributing misbranded drugs via the Internet has been sentenced to two years in fed...

latest-news-card-1
Medical Devices

Reclassify Some Oncology Panels: Petition

Foundation Medicine petitions FDA to reclassify all next-generation sequencing oncology panel devices used for somatic or germline variant detection t...

latest-news-card-1
Human Drugs

Petition Seeks Govt Action to Allow Generic Semaglutide

Public Citizen petitions HHS to use its authority under 28 USC. 1498 to permit generic competitors to manufacture Novo Nordisks semaglutide, the acti...

latest-news-card-1
Human Drugs

Drug Safety Committee Renewed

FDA renews the Drug Safety and Risk Management Advisory Committee for an additional two years.

latest-news-card-1
Human Drugs

Labcorp Gets De Novo for Tumor Assay

FDA grants Labcorp a de novo marketing authorization for its PGDx elio plasma focus Dx kitted assay.

latest-news-card-1
Medical Devices

Exactech Joint Replacement Device Recall Updated

FDA updates an Exactech recall involving its joint replacement devices manufactured between 2004 and 2021.

latest-news-card-1
Human Drugs

Rare Disease Status for Hyperoxaluria Drug: META

FDA grants META Pharmaceuticals a rare pediatric disease designation for META-001-PH, an investigational drug for treating primary hyperoxaluria.

latest-news-card-1
Biologics

Another Study Needed for Iomab-B BLA: FDA

FDA asks Actinium Pharmaceuticals for another Phase 3 study to support a BLA submission for Iomab-B in patients with active relapsed or refractory acu...